Analyst firms · Morgan Stanley · ARGX
Morgan Stanley ARGX price target and rating history
argenx SE (ARGX) · Health Care
Morgan Stanley rates argenx SE (ARGX) Overweight with a $700 price target, as of its latest action on Jul 3, 2025. It has published 7 rating actions on ARGX since August 2021, including 1 upgrade and 1 downgrade. Across 3 firms with a ARGX price target in the last 12 months, the median target is $1,185.
- Current rating
- Overweight
- Price target
- $700
- Median target, all firms
- $1,185
- Actions on ARGX
- 7
Morgan Stanley price target on ARGX
Every Morgan Stanley rating on ARGX
- Jul 3, 2025
- May 3, 2022
- Mar 7, 2022
- Feb 1, 2022
- Jan 18, 2022
- Sep 7, 2021
- Aug 3, 2021
How other firms rate ARGX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Buy | $1,400 | Aug 26, 2026 |
| Deutsche Bank | Hold | Aug 24, 2026 | |
| Guggenheim | Buy | $1,185 | Aug 4, 2026 |
| Robert W. Baird | Neutral | $858 | Dec 18, 2025 |
| Wolfe Research | Peer Perform | Nov 24, 2025 |
Questions about Morgan Stanley and ARGX
- What is Morgan Stanley's price target for ARGX?
- Morgan Stanley's latest stated price target for argenx SE (ARGX) is $700, from its action on Jul 3, 2025.
- What is Morgan Stanley's rating on ARGX?
- Morgan Stanley rates ARGX Overweight, a bullish rating, as of Jul 3, 2025.
- When did Morgan Stanley last change its view on ARGX?
- On Jul 3, 2025, Morgan Stanley resumes coverage at Overweight, price target $700.
- How does Morgan Stanley's ARGX target compare with other analysts?
- Across 3 firms with a ARGX price target in the last 12 months, the median target is $1,185.
More ARGX rating histories
All Morgan Stanley ratingsARGX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.